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Proteins with expanded polyglutamine (polyQ) seg-
ments cause a number of fatal neurodegenerative dis-
orders, including Huntington’s disease (HD). Previous
high-throughput screens in cellular and biochemical
models of HD have revealed compounds that mitigate
polyQ aggregation and proteotoxicity, providing insight
into the mechanisms of disease and leads for potential
therapeutics. However, the structural diversity of natu-
ral products has not yet been fully mobilized toward
these goals. Here, we have screened a collection of
~11 000 natural product extracts for the ability to
recover the slow growth of DProQ103-expressing yeast
cells in 384-well plates (Z’ ~ 0.7, CV ~ 8%). This
screen identified actinomycin D as a strong inhibitor of
polyQ aggregation and proteotoxicity at nanomolar
concentrations (~50–500 ng/mL). We found that a low
dose of actinomycin D increased the levels of the
heat-shock proteins Hsp104, Hsp70 and Hsp26 and
enhanced binding of Hsp70 to the polyQ in yeast. Acti-
nomycin also suppressed aggregation of polyQ in
mammalian cells, suggesting a conserved mechanism.
These results establish natural products as a rich
source of compounds with interesting mechanisms of
action against polyQ disorders.
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Nine related neurodegenerative diseases, including Hun-
tington’s disease (HD), are caused by genetic instability
and expansion of polyglutamine (polyQ) segments in key
proteins (1,2). In these diseases, the length of the polyQ
segment determines the severity and age-of-onset of
symptoms (3). For example, polyQ regions of ~40 residues
in the huntingtin protein lead to adult onset HD, while seg-
ments longer than 100 are observed in juvenile cases.
These elongated polyQ segments destabilize the disease-
associated proteins, such as huntingtin or the androgen
receptor, leading to misfolding, mislocalization and
aggregation (3–5). In turn, oligomers of the misfolded,
polyQ-containing protein are thought to disrupt numerous
essential cellular processes, including transcription and
protein turnover (6–9). Because of the numerous pathways
impacted by polyQ aggregation, it is thought that prevent-
ing the initial formation of oligomers might be the most
promising way to mitigate disease.
Expression of proteins with elongated polyQ segments
leads to the formation of proteotoxic aggregates in cul-
tured cells and animals, providing models for what occurs
in HD patients. These disease models have been particu-
larly useful for performing genetic screens (10–12), and
many of these screens have identified molecular chaper-
ones, such as heat-shock protein 70 (Hsp70) and heat-
shock protein 90 (Hsp90), as key regulators of polyQ
aggregation (13–15). For example, early studies in Saccha-
romyces cerevisae showed that overexpression of Hsp70
suppressed aggregation of an elongated polyQ fragment
containing 103 glutamines (Q103; 16–18). Similar studies
in other model systems, such as flies and mice, have con-
firmed this relationship (19–25). In addition to a role for
molecular chaperones, these genetic screens have also
pointed to important roles for the endocytosis and protein
turnover pathways (22,26–29). Together, these studies in
HD models have helped clarify the mechanisms of polyQ
aggregation and proteotoxicity (10,30).
Another use of polyQ models is in high-throughput chem-
ical screens. For example, Baldo et al. (31) recently used
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an engineered mouse hippocampal cell line (HN10) to
screen approximately two million Novartis compounds for
those that reduce the levels of a Q72 fragment. They
reported that inhibitors of Hsp90 substantially reduced
the levels of Q72 in embryonic stem cells and neurons,
suggesting a path toward clinical use of Hsp90 inhibitors
in HD. A conceptually similar screen was performed in a
S. cerevisae model; a library of commercial 16 000 com-
pounds was screened for those that restore the slow
growth of cells expressing Q103 (32). Other screens have
identified molecules that directly inhibit aggregation of pol-
yQ fragments, using in vitro formats (33,34) and cell-
based fluorescence resonance energy transfer (FRET; 35)
and high-content screening (HCS; 36) assays. Together,
these studies have provided promising lead compounds
for drug discovery in HD and other polyQ disorders
(18,32,37,38). Moreover, these chemical screens have
also provided unexpected insights into the mechanisms
of polyQ toxicity. For example, the Novartis screen found
that Hsp90 inhibitors reduced Q72 levels without a
requirement for a stress response (31), while the FRET
screen identified a ROCK/p160 inhibitor as a potent sup-
pressor of polyQ (36).
Natural product collections have historically provided struc-
turally diverse and bioactive lead structures for the treat-
ment of many diseases (39). It has been estimated that
60% of current FDA-approved drugs have origins in natu-
ral products, illustrating the power of these compounds in
drug discovery. Surprisingly, a screen of natural product
extracts in polyQ models has not been reported. Accord-
ingly, we have taken advantage of a newly developed
yeast model (40) to screen a collection of ~11 000 prefrac-
tionated natural product extracts in 384-well plates. This
assay required optimization of the growth conditions to
achieve good screening statistics, and the resulting proto-
col provided a robust ‘live-dead’ HTS methodology (Z’ fac-
tor 0.7; CV 8%). Moreover, this screen identified
actinomycin D as a molecule that disrupts polyQ aggrega-
tion and reverses growth defects at low nanomolar con-
centrations. Initial mechanistic studies suggest that this
molecule might suppress polyQ, in part, by increasing
chaperone levels and enhancing binding to Hsp70.
Materials and Methods
Yeast strains
The yeast strain used in this study was YKO (pdr5D;
MATa/MATa orf::kanMX4/orf::kanMX4 ura3D0/ura3D0 leu2
D0/leu2D0 his3D1/his3D1 met15D0/MET15 lys2D0/LYS2).
The pdr5D strain was used to enhance compound
potency for the HTS efforts. The plasmids and methods
used were originally developed by the Lindquist’s group
and reported in recent manuscripts (16,18,40–42). Briefly,
these plasmids enable galactose-inducible (GAL1) expres-
sion of DProQ25-CFP, DProQ103-CFP, Q25-GFP or
Q103-GFP.
Antibodies
Antisera against Hsp26 and Hsp104 were a kind gift from
the laboratories of Johannes Buchner and Stefan Walter.
Antibodies to Hsp70 (3A3) and Hsp90 were purchased
from Santa Cruz Biotechnology.
Isolation of extracts
Strain 07-15-H3 was isolated from a Papua New Guinea
marine sediment as described (43). The initial extracts
were generated by growing the microbe in 100 mL of X1
media (0.25 g dextrose, 0.25 g yeast extract, 0.64 g malt
extract, 30 g sodium chloride, 1 L H2O) in a 250-mL baf-
fled flask on a rotary shaker at 200 rpm for 20 days.
These cultures were centrifuged and the fermentation
medium was extracted with amberlite XAD-16 resin. The
resin was washed and then extracted with methanol (to
produce SID#13569), acetone and ethanol. For active
compound identification, the same microbe was grown in
2.5 L of ISP2 (4 g dextrose, 4 g yeast extract, 10 g malt
extract, 30 g sodium chloride and 1 L d-H2O) in a 6-L
flask at 200 rpm on a rotary shaker for 20 days, followed
by the same extraction procedure.
High-throughput screen
Cultures harboring DProQ103 plasmid where grown over-
night under selection (SC His() media with 2% glucose),
as described elsewhere (41). The following morning, the
cells were centrifuged (500 9g), washed with dH2O and
resuspended in SC His() media plus 2% raffinose. After
3 h at 30 °C, the OD600 was determined and a 2X inocu-
lum culture was prepared by diluting to OD600 = 0.12 in
SC His() media plus 2% raffinose and 2% galactose.
Finally, assay plates were prepared by adding 20 lL of
SC His() media plus 2% raffinose and 2% galactose to
sterile, clear, medium binding 384-well plates (Corning
3680) using a Multidrop 384 dispenser (Thermo Labsys-
tems, Waltham, MA, USA). Wells containing SC His()
media and 4% raffinose were served as the positive con-
trol. Natural product extracts (15 mg/mL) were added in
0.2 lL of DMSO using a Beckman Biomek FX with a
384 HDR pintool. An aliquot (20 lL) of the 2X yeast cul-
ture was then added using the Multidrop 384 dispenser,
and the plates were centrifuged for 1 min at 250 9g to
start the experiment. These plates were incubated in a
humidified chamber at 30 °C for 48 h. Cell growth was
determined by OD600 using a BMG Pherastar plate
reader. The retesting of samples for progrowth activity
was performed using an identical protocol.
Fluorescence microscopy
Microscopy experiments were conducted as previously
described (41,42). Images were collected 1.5 h after 2%
galactose induction for the Q103-GFP-expressing cells or
3 h after 2% galactose induction for the DProQ103-
expressing cells. Cells lacking clear puncta were scored
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from randomly selected fields and reported as a fraction of
the total number of cells (n = 200).
Isolation of the active compound
The methanol extract SID#13569 was fractionated on a
C18 LOBAR LiChroprep column using MeOH/water (7:3),
and fraction 7 was further fractionated by HPLC on an
XBridge Prep C18 column under the same solvent condi-
tions. The chemical structure of the major compound in
fraction 7 was determined by mass spectra and NMR (1H,
13C and 2D spectra). The test sample had an m/z value
consistent with actinomycin D (1277.7 [M+Na]), and a
comparison of the test sample with authentic actinomycin
D (Sigma #A12110; lot #071M21028V, St. Louis, MO,
USA) showed good correlation of the peaks (Figure S1).
The mass spectra were collected on a Micromass Auto-
Spec Ultima Magnetic spectrometer (Waters Corp, Plea-
santon, CA, USA). The NMR spectra were collected in
CD3OD on a Varian INOVA 600 MHz NMR spectrometer
(Palo Alto, CA, USA), using TMS as an internal standard.
Immunoprecipitations
The co-immunoprecipitations and Western blotting proce-
dures have been described previously (18). Results were
quantified using NIH IMAGE J and normalized to an actin
loading control (Figure 4A) or anti-FLAG blot (Figure 4C).
Beta-galactosidase assays
For the b-galactosidase assay, cells were grown to mid-
log phase in selective media followed by dilution to
OD600 = 0.3. Cells were cultured for 3.5 h at 30 °C prior
to sample preparation. The b-galactosidase assay was
performed according to the manufacturer (Thermo Fisher
Scientific, Waltham, MA, USA).
PolyQ aggregation assay in PC12 cells
Experiments were performed in inducible PC12 cells
(14A2.5) expressing truncated huntingtin exon 1 containing
103Q repeats and fused to EGFP (36). Cells were main-
tained in DMEM, 10% horse serum, 5% fetal bovine serum,
1% penicillin/streptomycin with continual selection in
200 lg/ml geneticin. For the aggregation assay, cells were
induced with 5 lM ponasterone A (Invitrogen, Carlsbad, CA,
USA) for 30 h prior to treatment with compounds. Stock
solutions of actinomycin D (Sigma A1410), tunicamycin
(Sigma) and YM1 were prepared in DMSO. Cycloheximide
(Sigma) was prepared in ddH2O at 1 mg/ml immediately
prior to use. Compounds were added to culture media at
the final concentrations indicated. Aggregates were
assessed 48 h after polyQ induction by fluorescence
microscopy on a Nikon Ti-E microscope equipped with a
Coolsnap HQ2 CCD camera (Photometrics, Tuscon, AZ,
USA). Aggregates were quantified with the spot detection
feature in NIS-Elements software (Nikon, Tokyo, Japan).
Greater than 300 cells, imaged from three fields, were ana-
lyzed per data point for each experiment.
Results and Discussion
Development of a high-throughput screen
In this study, we adapted a long polyQ construct
(DProQ103) and a short polyQ construct (DProQ25) that
were reported for use in yeast by the Lindquist group (40).
These polyQ fragments are galactose inducible and
expressed as fusions with the cyan fluorescent protein
(CFP) to allow visualization of the proteins. Also, they lack
the proline-rich domain of native huntingtin, which
changes the aggregation propensity of DProQ103 protein
(44) and exaggerates its growth defect phenotype in yeast
(40). The shorter, inert DProQ25 protein also expresses at
a comparable level to DProQ103, providing a good control
for aggregation and proteotoxicity. Consistent with the pre-
vious findings, we confirmed that expression of DProQ103,
but not the DProQ25 fragment, leads to slow growth of
S. cerevisae (strain YKO; pdr5D) in both colony formation
(Figure 1A) and liquid culture assays (Figure 1B). The
pdr5D strain was used to maximize compound efficacy in
anticipation of high-throughput chemical screens, and this
strain background did not appear to diminish the polyQ-
mediated growth effects.
Using this system, we envisioned that the liquid culture
assay might be particularly suitable for high-throughput
screening (HTS). Miniaturization of 96-well growth assays
into HTS compatible, 384-well format often requires sub-
stantial reoptimization of conditions because of the differ-
ences in surface area at low volume. The goal of our
particular optimization strategy was to produce the great-
est difference between the growth of the DProQ25 and
DProQ103 strains after induction of the polyQ fragments.
Toward that goal, we systematically varied assay condi-
tions, such as the initial inoculum density of the culture
(between 0.03 and 0.3 OD600), incubation time (between
24 and 72 h), carbon source (varying ratios of raffinose
and/or galactose) and total carbon concentration (total
amount of raffinose and/or galactose; Figure S1). Using
this approach, we determined that an initial inoculum den-
sity of 0.06, incubated for 48 h, in SC His() media with
2% raffinose and 2% galactose produced the optimum
signal/background differential (see the Materials and Meth-
ods for details).
Using these conditions, we screened ~11 000 prefraction-
ated natural product extracts at concentrations around
100 lg/mL. The extract collection was assembled from
bacterial and fungal sources isolated from Papua New
Guinea, Costa Rica and other locations, as previously
described (45). Samples from this collection have been
used to identify promising lead compounds in other
screens (46), including unexpected uses for known mole-
cules. In yeast expressing DProQ103, we identified 29
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extracts that improved growth by more than 20% and
four extracts that improved growth by at least 30% (Fig-
ure 1C). We also noted that a number of extracts
decreased growth below the level of the mock-treated
controls, suggesting that they might be cytotoxic. Overall,
this assay yielded excellent screening characteristics (Z’
factor ~ 0.7, CV% ~ 8%). Moreover, it was inexpensive,
required no detection reagents, and likely because active
molecules must increase (rather than decrease) growth
rates, the assay had a low ‘hit rate’ (>20% growth recov-
ery = 0.3% actives). This modest rate is especially impor-
tant in screens of prefractionated natural product extracts
Sample screening results from ~11 000 extracts
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Figure 1: Results of a yeast-based high-throughput screen (HTS) for suppression of polyQ growth defects and confirmation of two active
extracts. (A) Expression of an expanded polyQ fragment (DProQ103), but not the normal length DProQ25, in Saccharomyces cerevisae
suppresses growth in colony dilution assays. Both constructs are expressed as cyan fluorescent protein (CFP) fusions under the control of
a galactose-inducible promoter. (B) Expression of DProQ103, but not DProQ25, suppresses yeast growth in liquid culture. (C) Sample of
the HTS results. A library of 11 000 prefractionated natural product extracts was screened in 384-well plates at approximately 100 lg/mL.
Results are shown relative to uninduced controls (i.e., grown in 4% raffinose; no DProQ103 expression) and DMSO-treated controls. The
screening statistics are shown. (C) The four most active extracts (>30% growth in the primary screen) were rescreened in triplicate (left)
and tested at multiple dilutions (right). Two of the extracts were confirmed (SID #13569 and 17432). (D) By fluorescence microscopy,
treatment with either of the active extracts disrupted the formation of puncta in some yeast. Aggregates are indicated by white arrows,
and the percentage of cells with diffuse fluorescence is indicated (n = 200 cells). Scale bar is 2 lm.
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because the identification of the active component is
often a time-intensive task.
Focusing on the four most active extracts, we rescreened
parent stocks at 100 lg/mL and found that SID#13569
and SID#17432 were reproducible inhibitors of the
DProQ103 growth phenotype at multiple dilutions (Fig-
ure 1D). To ascertain whether these extracts impacted the
aggregation of polyQ in the treated cells, we performed
fluorescence microcopy studies. Consistent with recent
reports, DProQ103-CFP fluorescence appeared as multi-
ple, discrete puncta in mock-treated cells (Figure 1E).
However, both SID#17432 and SID#13569 altered the flu-
orescence pattern, increasing the number of cells with dif-
fuse fluorescence by approximately 2.5- and 5.5-fold,
respectively (Figure 1E). Based on these results, the frozen
spores of the original producer organisms were regrown
under the original conditions and fresh extracts prepared
(see the Materials and Methods). The producer organism
for SID#17432 did not regrow (data not shown), but the
fresh extract of SID#13569 retained activity and was fur-
ther explored.
Bioactivity-guided fractionation of a promising
extract
High-performance liquid chromatography (HPLC)-based
crude separation of the SID#13569 extract resulted in
ten fractions, which were then tested for bioactivity in
the fluorescence microscopy-based assay. In these
experiments, we switched from using the DProQ103
construct to a Q103-GFP fusion. The Q103-GFP fusion
is less toxic and typically produces a single puncta per
cell (16), making it easier to visually score the results.
Using this approach, we found that a number of the
fractions contained active compound (Figure 2). The early
fractions (#2 through 4) appeared to contain a complex
mixture of compounds, as estimated by HPLC (data not
shown), so we focused on identifying the active compo-
nent in fraction 7 that only contained a single peak
(Figure 2A).
To chemically characterize the active component of frac-
tion 7, we performed additional purification by HPLC (see
the Materials and Methods). One pure fraction (0715-H3)
contained a molecule with a molecular mass of 1277.7 (m/
z), corresponding with the sodium form of actinomycin D
([M+Na] = 1277.7; Figure 2B; Figure S2). Proton NMR-
based comparison with commercially available actinomycin
D (Sigma #A12110; lot #071M21028V) further suggested
that this compound might be the active component (Fig-
ure S2). Actinomycin D is a well known inhibitor of tran-
scription that binds ssDNA in the transcription initiation
complex (47).
Actinomycin D recovers yeast growth and
suppresses aggregation
To test whether actinomycin D might be the active compo-
nent of SID#13569, we measured the activity of commer-
cially available compound (Sigma #A12110) in the yeast
growth and fluorescence microscopy assays. These stud-
ies revealed that actinomycin D had a remarkable potency,
recovering normal growth of DProQ103-expressing cells at
~40 nM (EC50 ~ 50 ng/mL; Figure 3A). At levels higher
than 5 or 50 lg/mL, toxicity was observed, likely because
of translational inhibition (47). In the fluorescence micros-
copy assay, actinomycin D also strongly suppressed polyQ
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Figure 2: Bioassay-guided fractionation and identification of an active compound. (A) Using fluorescent puncta in yeast expressing Q103-
GFP as a guide, the active HPLC fractions in crude extracts of SID#13569 were determined. Representative images are shown, and the
arrows indicate puncta. Scale bar is 2 lm. The results were quantified by counting more than 200 yeast from random fields and scoring
individual cells for the presence of well-resolved puncta. (B) The chemical structure of actinomycin D.
444 Chem Biol Drug Des 2014; 83: 440–449
Walter et al.
Authentic actinomycin D improves growth of
ΔProQ103-expressing cells
Co
nt
ro
l
Un
-in
du
ce
d 
G
ro
w
th
 (%
)
Actinomycin D (µg/mL)
50 5 0.
5
0.
05
0.
00
5
0.
00
05
0.
00
00
5
100
80
60
40
20
0
0
20
40
60
80
100
5 µg/mL DMSO0.0005 µg/mL 0.005 µg/mL 0.5 µg/mL
D
IC
Q
10
3P
-G
FP
Actinomycin D disrupts aggregation of Q103-GFP in yeast
5 
DM
SO
0.0
005 500.0
05 0.5
 
0.0
000
5
0.0
5
D
iff
us
e 
(%
)
Actinomycin D (µg/mL)
A B
Figure 3: Confirmation of actinomycin D as an active compound. (A) Authentic actinomycin D (Sigma #A12110) improved growth of
yeast expressing DProQ103. Results are representative of experiments performed in triplicate. Uninduced cells were grown in 4%
raffinose. (B) Actinomycin D blocked the formation of puncta in cells expressing Q103-GFP. Representative images are shown, with
puncta indicated by white arrows. Scale bar is 2 lm. For quantifications, more than 200 yeast cells were examined and scored for the
presence of puncta.
Hsp104
Hsp70
Hsp26
0.0050.050.5
Actinomycin D (µg/mL)
Q103P
Low doses of actinomycin D activate
a stress response in yeast
Hsp104
Hsp70
Hsp26
Actinomycin D enhances Hsp70
 binding to Q103P-GFP 
in
te
ns
ity
 (a
u)
0.0050.050.5
Actinomycin D (µg/mL)
Hsp104
Hsp70
Hsp26
control
Actinomycin D
(0.005 µg/mL)
untreated heat shock
(37 °C)
be
ta
-g
al
ac
to
si
da
se
 a
ct
iv
ity
 (µ
m
ol
/m
g/
m
in
)
0.0050.050.5
Actinomycin D (µg/mL)
Q103P
control
1
0.8
0.6
0.4
0.2
0 in
te
ns
ity
 (a
u)
0.0050.050.5
Actinomycin D (µg/mL)
Hsp104
Hsp70
Hsp26
Actinomycin D activates a beta-
galactosidase stress reporter
4
3
2
1
4
3
2
1
A B C
Figure 4: Suppression of polyQ toxicity and aggregation in yeast involves activation of a stress response and altered chaperone
interactions. (A) Low doses of actinomycin D activate a stress response, as measured by Western blots for the stress markers Hsp26,
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Q103-GFP, as measured by co-immunoprecipiation of a FLAG epitope on Q103P-GFP.
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aggregation at concentrations between ~0.5 and
0.0005 lg/mL, with activity reduced at both higher and
lower levels (Figure 3B).
Actinomycin D activates a stress response at low
concentrations
The simplest mechanistic explanation for these observa-
tions is that actinomycin D suppresses transcription of the
polyQ fragment, relieving growth suppression by reducing
the levels of polyQ protein. However, actinomycin D is only
active as a transcriptional suppressor in S. cerevisae at
~50 lg/mL (40 lM; 48, 49). In contrast, we observed anti-
polyQ activity at concentrations that were at least 100-fold
lower (see Figure 3). Further, there was not any significant
change in the total amount of polyQ-CFP protein or RNA
in cells treated with 50 ng/mL actinomycin D for 1.5 h, as
estimated by CFP fluorescence intensity (~93  8% of
untreated) or RT-PCR for the CFP mRNA (91  11% of
untreated), respectively. Thus, although transcriptional
attenuation is likely to be one contributing mechanism,
there appeared to be an additional pathway leading to pol-
yQ suppression in this system.
We hypothesized that low doses of actinomycin D might
reduce polyQ aggregation and toxicity by activating a
stress response. Cellular stress, such as exposure to high
temperatures or heavy metals, causes upregulation of
many protective heat-shock proteins, such as Hsp26,
Hsp70 and Hsp104 (50). These chaperones are known to
prevent proteotoxicity caused by expression of polyQ frag-
ments (16,41,51). Further, pharmacological activation of a
stress response has previously been reported to impact
polyQ aggregation in other models (37,38,52). To test
whether actinomycin D might cause a heat-shock
response at low concentrations, we measured the levels
of the stress markers, Hsp26, Hsp70 and Hsp104, by
Western blots. At concentrations of 0.05 and 0.005 lg/
mL, actinomycin D was a potent activator of heat-shock
proteins, increasing the levels of Hsp104 by fourfold and
the levels of Hsp70 and Hsp26 by at least twofold (Fig-
ure 4A). Similarly, a beta-galactosidase reporter of the
stress response (STRE) confirmed that actinomycin D
(0.005 lg/mL) was a potent activator (Figure 4B).
Hsp70 is known to be upregulated by the stress pathway,
and this chaperone directly binds polyQ fragments to miti-
gate aggregation (18). Therefore, we tested whether acti-
nomycin D treatment might enhance the binding of Hsp70
to DProQ103 by co-immunoprecipitation (co-IP). The
results showed that Hsp70 binding was enhanced more
than threefold after treatment with low doses of actinomy-
cin D (Figure 4C). Binding of DProQ103 to Hsp104 was
also increased (Figure 4C). While it is likely that other
mechanisms are also involved, activation of a stress
response and increased Hsp70 binding by low doses of
actinomycin D appeared to be one contributing factor in
suppressing polyQ aggregation and proteotoxicity.
Actinomycin D suppressed polyQ aggregation in
mammalian cells
To investigate whether this mechanism might be
conserved in mammalian cells, we tested the effects of
actinomycin D on polyQ aggregation in a PC12 model
(36). Similar to what was observed in yeast, low levels of
actinomycin D (4–100 ng/mL) suppressed aggregation,
while higher and lower concentrations were inactive (Fig-
ure 5A). These results suggest that the pathway for actino-
mycin D’s antipolyQ activity may be conserved.
Conclusions
There is no cure for Huntington’s disease (HD) or any of
the other polyQ disorders. Toward that goal, a number of
HTS methods have been previously developed and used to
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Figure 5: Suppression of polyQ aggregation in mammalian PC12
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is observed at 48 h after induction. Low concentrations of
actinomycin D (4–100 ng/mL) reduced the number of cells with
aggregates. Scale bar = 50 lm. (B) Quantification of the
percentage of PC12 cells with aggregates averaged from three
independent experiments SEM.
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identify promising leads (31–36). In this work, we focused
on screening prefractionated natural product extracts as a
potential source of molecules with antipolyQ activity. We
were able to develop a robust, low-cost HTS protocol that
was ideally suited for testing natural product collections
because it readily removed cytotoxic fractions. We found
that the key technical consideration was careful control
over the yeast growth rate, especially by selecting the
proper inoculation density and total carbon concentration.
These HTS efforts identified actinomycin D as a potent
inducer of the stress response that was able to block pol-
yQ aggregation and growth defects in yeast and reduce
the number of cells with puncta in mammalian cells.
Although it isn’t yet clear how actinomycin D activates a
stress response (see Figure 4), we speculate that low con-
centrations of the compound might modestly and non-
specifically inhibit transcription, leading to the accumula-
tion of truncated mRNA and perhaps shortened gene
products. Although the direct utility of actinomycin D as a
drug lead for HD or other polyQ disorders is uncertain,
these studies provide further support for the stress
response as an important pathway impacting polyQ toxic-
ity (20,37,53). Thus, these studies lend impetus to ongoing
efforts targeting the stress response, such as compounds
targeting the major stress transcription factor (20,54,55)
and those targeting proteins in the unfolded protein sys-
tem (46,56). Our results suggest that molecules identified
by these efforts may upregulate Hsp70 and suppress pol-
yQ proteotoxicity.
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